{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:09:38Z","timestamp":1780927778095,"version":"3.54.1"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ejps.2017.10.009","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T00:31:46Z","timestamp":1507854706000},"page":"465-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex"],"prefix":"10.1016","volume":"111","author":[{"given":"Todd M.","family":"Conner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahagn C.","family":"Nikolian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick E.","family":"Georgoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath P.","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan B.","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2017.10.009_bb0005","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/psp4.12102","article-title":"A tutorial on pharmacodynamic scripting facility in Simcyp","volume":"5","author":"Abduljalil","year":"2016","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0010","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s002280000211","article-title":"Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers","volume":"56","author":"Addison","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0015","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.bbalip.2007.01.010","article-title":"Studies on the extra-mitochondrial CoA-ester formation of valproic and 4-ene-valproic acids","volume":"1771","author":"Aires","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejps.2017.10.009_bb0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1528-1157.1991.tb05624.x","article-title":"Effect of felbamate on plasma concentrations of carbamazepine and its metabolites","volume":"32","author":"Albani","year":"1991","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2017.10.009_bb0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/dmd.108.022426","article-title":"Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10","volume":"37","author":"Argikar","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.10.009_bb0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00007691-199904000-00008","article-title":"Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications","volume":"21","author":"Armijo","year":"1999","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2017.10.009_bb0035","first-page":"629","article-title":"Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults","volume":"38","author":"Bano","year":"1990","journal-title":"J. Assoc. Physicians India"},{"key":"10.1016\/j.ejps.2017.10.009_bb0040","first-page":"403","article-title":"Plasma levels of di-no-propylacetate and clonazepam in epileptic patients","volume":"15","author":"Baruzzi","year":"1977","journal-title":"Int. J. Clin. Pharmacol. Biopharm."},{"key":"10.1016\/j.ejps.2017.10.009_bb0045","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/j.1552-4604.1995.tb04020.x","article-title":"A model for estimating individualized valproate clearance values in children","volume":"35","author":"Botha","year":"1995","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9343(88)90054-X","article-title":"Pharmacologic interactions between valproate and other drugs","volume":"84","author":"Bourgeois","year":"1988","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejps.2017.10.009_bb0055","series-title":"Antiepileptic Drugs","first-page":"808","article-title":"Valproic acid: clinical efficacy and use in epilepsy","author":"Bourgeois","year":"2002"},{"key":"10.1016\/j.ejps.2017.10.009_bb0060","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1111\/j.1528-1157.1987.tb05769.x","article-title":"Monotherapy with valproate in primary generalized epilepsies","volume":"28","author":"Bourgeois","year":"1987","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2017.10.009_bb0065","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/clpt.1980.192","article-title":"Valproic acid dosage and plasma protein binding and clearance","volume":"28","author":"Bowdle","year":"1980","journal-title":"Clin. Pharmacol. Ther."},{"issue":"Suppl. 2","key":"10.1016\/j.ejps.2017.10.009_bb0070","article-title":"Road to refractory epilepsy: the Glasgow story","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2017.10.009_bb0075","series-title":"Antiepileptic Drugs","first-page":"565","article-title":"Phenytoin and other hydantoins: chemistry and biotransformation","author":"Browne","year":"2002"},{"key":"10.1016\/j.ejps.2017.10.009_bb0080","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2125.1983.tb02151.x","article-title":"Pharmacokinetics of valproic acid in young and elderly subjects","volume":"16","author":"Bryson","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/j.1552-4604.1980.tb01663.x","article-title":"Bioavailability of valproic acid under fasting\/nonfasting regimens","volume":"20","author":"Chun","year":"1980","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-1211(02)00251-6","article-title":"Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy","volume":"53","author":"Cloyd","year":"2003","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2017.10.009_bb0095","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1128\/AAC.48.11.4328-4331.2004","article-title":"Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults","volume":"48","author":"Di Cenzo","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2017.10.009_bb0100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00007691-198903000-00002","article-title":"Urinary excretion of valproate and some metabolites in chronically treated patients","volume":"11","author":"Dickinson","year":"1989","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2017.10.009_bb0105","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00044011-200424090-00001","article-title":"Divalproex to divalproex extended release conversion","volume":"24","author":"Dutta","year":"2004","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ejps.2017.10.009_bb0110","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00044011-200626120-00002","article-title":"Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug: as shown by once-daily divalproex-ER","volume":"26","author":"Dutta","year":"2006","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ejps.2017.10.009_bb0115","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1177\/0091270004266782","article-title":"Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers","volume":"44","author":"Dutta","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/bdd.421","article-title":"Comparison of the bioavailability of 250 and 500mg divalproex sodium extended-release tablets in healthy volunteers","volume":"25","author":"Dutta","year":"2004","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2017.10.009_bb0125","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1093\/ajhp\/61.21.2280","article-title":"Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration","volume":"61","author":"Dutta","year":"2004","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejps.2017.10.009_bb0130","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pediatrneurol.2003.12.006","article-title":"Divalproex-ER pharmacokinetics in older children and adolescents","volume":"30","author":"Dutta","year":"2004","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0135","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/jps.20387","article-title":"Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC)","volume":"94","author":"Dutta","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.10.009_bb0140","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0006-2952(03)00076-5","article-title":"The effect of valproic acid on drug and steroid glucuronidation by expressed UDP-glucuronosyltransferases","volume":"65","author":"Ethell","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0145","first-page":"17","article-title":"A long-term study of monotherapy with sodium valproate in primary generalized epilepsy","volume":"27","author":"Feuerstein","year":"1983","journal-title":"Br. J. Clin. Pract."},{"key":"10.1016\/j.ejps.2017.10.009_bb0150","article-title":"Safety and tolerability of intravenous valproic acid in healthy subjects: a phase I dose-escalation trial","author":"Georgoff","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.10.009_bb0155","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.ejps.2017.10.009_bb0160","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2710.1995.tb00651.x","article-title":"Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy","volume":"20","author":"Gidal","year":"1995","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejps.2017.10.009_bb0165","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1528-1157.1979.tb04808.x","article-title":"Sodium valproate, serum level and clinical effect in epilepsy: a controlled study","volume":"20","author":"Gram","year":"1979","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2017.10.009_bb0170","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2125.1978.tb01652.x","article-title":"Plasma protein binding of valproic acid in healthy subject and in patients with renal disease","volume":"5","author":"Gugler","year":"1978","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0175","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/00003088-198005010-00002","article-title":"Clinical pharmacokinetics of valproic acid","volume":"5","author":"Gugler","year":"1980","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.10.009_bb0180","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/bdd.1777","article-title":"PBPK as a tool in regulatory review","volume":"33","author":"Huang","year":"2012","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2017.10.009_bb0185","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/clpt.2011.320","article-title":"The role of physiologically based pharmacokinetic modeling in regulatory review","volume":"91","author":"Huang","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.10.009_bb0190","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/bdd.2510140505","article-title":"Effect of infusion duration on valproate pharmacokinetics","volume":"14","author":"Hussein","year":"1993","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2017.10.009_bb0195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10928-013-9323-3","article-title":"Sex related differences on valproic acid pharmacokinetics after oral single dose","volume":"40","author":"Ibarra","year":"2013","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2017.10.009_bb0200","first-page":"1083","article-title":"Preliminary observations on valproic acid kinetics in patients with epilepsy","volume":"27","author":"Johannessen","year":"1977","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejps.2017.10.009_bb0205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1586\/ecp.12.10","article-title":"Methodologies used to identify and characterize interactions among antiepileptic drugs","volume":"5","author":"Johannessen Landmark","year":"2012","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0210","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1208\/s12248-009-9088-1","article-title":"Modelling and PBPK simulation in drug discovery","volume":"11","author":"Jones","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2017.10.009_bb0215","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/cpt1977216736","article-title":"Pharmacokinetics and bioavailability of sodium valproate","volume":"21","author":"Klotz","year":"1977","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.10.009_bb0220","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00606683","article-title":"Disposition of valproic acid in patients with liver disease","volume":"13","author":"Klotz","year":"1978","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0225","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2017.10.009_bb0230","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/bdd.2510140409","article-title":"Dual effect of valproic acid on the pharmacokinetics of phenytoin","volume":"14","author":"Lai","year":"1993","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2017.10.009_bb0235","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.2147\/DDDT.S89464","article-title":"Effects of amoxicillin\/clavulanic acid on the pharmacokinetics of valproic acid","volume":"9","author":"Lee","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejps.2017.10.009_bb0240","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/clpt.2012.19","article-title":"Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials","volume":"91","author":"Leong","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.10.009_bb0245","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/clpt.1990.144","article-title":"Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid","volume":"48","author":"Levy","year":"1990","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.10.009_bb0250","series-title":"Antiepileptic Drugs","first-page":"780","article-title":"Valproid acid: chemistry, biotransformation, and pharmacokinetics","author":"Levy","year":"2002"},{"key":"10.1016\/j.ejps.2017.10.009_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.210","article-title":"Slow drug delivery decreased total body clearance and altered bioavailability of immediate- and controlled-release oxycodone formulations","volume":"4","author":"Li","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ejps.2017.10.009_bb0260","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1528-1157.1975.tb04743.x","article-title":"Concentration of dipropylacetate in plasma","volume":"16","author":"Loiseau","year":"1975","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2017.10.009_bb5005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0022-3565(25)31137-7","article-title":"Serum-protein binding and pharmacokinetics of Valproate in man, dog, rat and mouse","volume":"204","author":"Loscher","year":"1978","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.ejps.2017.10.009_bb0265","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1528-1157.1991.tb05619.x","article-title":"Antiepileptic drug intoxication: factors and their significance","volume":"30","author":"Manon-Espaillat","year":"1991","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2017.10.009_bb0270","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00007691-198512000-00004","article-title":"Serum concentrations of valproic acid: influence of dose and comedication","volume":"7","author":"May","year":"1985","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2017.10.009_bb0275","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00007691-199610000-00001","article-title":"Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication","volume":"18","author":"May","year":"1996","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2017.10.009_bb0280","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/003693308202700410","article-title":"Plasma levels of sodium valproate in childhood epilepsy","volume":"27","author":"McQueen","year":"1982","journal-title":"Scott. Med. J."},{"key":"10.1016\/j.ejps.2017.10.009_bb0285","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079906X162773","article-title":"Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol","volume":"23","author":"Murthy","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejps.2017.10.009_bb0290","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejps.2017.10.009_bb0295","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1528-1157.1982.tb05063.x","article-title":"The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers","volume":"23","author":"Nitsche","year":"1982","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2017.10.009_bb0300","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/j.1552-4604.1992.tb03889.x","article-title":"Circadian changes of valproate kinetics depending on meal condition in humans","volume":"32","author":"Ohdo","year":"1992","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0305","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2125.1989.tb05372.x","article-title":"The effect of carbamazepine on valproic acid disposition in adult volunteers","volume":"27","author":"Panesar","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0310","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs)\u2014part 1: pharmacokinetic and pharmacodynamic interactions between AEDs","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.10.009_bb0315","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-013-0088-z","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs)\u2014part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.10.009_bb0320","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","article-title":"Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0325","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","article-title":"Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0330","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","article-title":"The importance of drug interactions in epilepsy therapy","volume":"43","author":"Patsalos","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2017.10.009_bb0335","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2125.1996.tb00046.x","article-title":"The new generation of antiepileptic drugs: advantages and disadvantages","volume":"42","author":"Perucca","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0340","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs","volume":"61","author":"Perucca","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0345","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2125.1978.tb01663.x","article-title":"Disposition of sodium valproate in epileptic patients","volume":"5","author":"Perucca","year":"1978","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0350","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1528-1167.2008.01665.x","article-title":"Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy","volume":"49","author":"Perucca","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2017.10.009_bb0355","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/bdd.2510140108","article-title":"Pharmacokinetic interaction between valproic acid and phenobarbital","volume":"14","author":"Pokrajac","year":"1993","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2017.10.009_bb0360","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/jps.10385","article-title":"Once-a-day controlled-release dosage form of divalproex sodium I: formulation design and in vitro\/in vivo investigations","volume":"92","author":"Qiu","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.10.009_bb0365","series-title":"Milestones in Drug Therapy - Valproate","first-page":"91","article-title":"Toxicity","author":"Radatz","year":"1999"},{"key":"10.1016\/j.ejps.2017.10.009_bb0370","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1124\/jpet.110.167916","article-title":"In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans","volume":"334","author":"Raungrut","year":"2010","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.ejps.2017.10.009_bb0375","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eplepsyres.2009.09.015","article-title":"Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy","volume":"87","author":"Reed","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2017.10.009_bb0380","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3346\/jkms.1993.8.4.251","article-title":"Pharmacokinetic comparison of two valproic acid formulations","volume":"8","author":"Rha","year":"1993","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.ejps.2017.10.009_bb0385","series-title":"Clinical and Pharmacological Aspects of Sodium Valproate (Epilim) in the Treatment of Epilepsy","first-page":"78","article-title":"Pharmacokinetics and efficacy of Epilim in patients receiving long-term therapy with other antiepileptic drugs","author":"Richens","year":"1976"},{"key":"10.1016\/j.ejps.2017.10.009_bb0390","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.10.009_bb0395","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1528-1157.1981.tb06154.x","article-title":"Reduction of steady-state valproate levels by other antiepileptic drugs","volume":"22","author":"Sackellares","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2017.10.009_bb0400","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/j.1552-4604.1997.tb04322.x","article-title":"Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam","volume":"37","author":"Samara","year":"1997","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0405","first-page":"31","article-title":"Valproic acid clearance in children with epilepsy","volume":"23","author":"S\u00e1nchez-Alcaraz","year":"1998","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejps.2017.10.009_bb0410","series-title":"Antiepileptic Drugs","first-page":"801","article-title":"Valproic acid: drug interactions","author":"Scheyer","year":"2002"},{"key":"10.1016\/j.ejps.2017.10.009_bb0415","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00007691-199003000-00001","article-title":"In vivo determination of valproate binding constants during sole and multi-drug therapy","volume":"12","author":"Scheyer","year":"1990","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2017.10.009_bb0420","doi-asserted-by":"crossref","first-page":"g2546","DOI":"10.1136\/bmj.g254","article-title":"Drug treatment of epilepsy in adults","volume":"348","author":"Schmidt","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ejps.2017.10.009_bb0425","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00561557","article-title":"Pharmacokinetics of di-n-propylacetate in epileptic patients","volume":"8","author":"Schobben","year":"1975","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0430","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1212\/WNL.42.3.582","article-title":"Low and variable presence of valproic acid in human brain","volume":"42","author":"Shen","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.ejps.2017.10.009_bb0435","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review","volume":"31","author":"Silva","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ejps.2017.10.009_bb0440","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/clpt.2014.46","article-title":"Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy","volume":"95","author":"Sinha","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.10.009_bb5000","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/jpet.301.1.382","article-title":"In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance","volume":"301","author":"Soars","year":"2002","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.ejps.2017.10.009_bb0445","first-page":"139","article-title":"Steady-state serum concentrations of carbamazepine and valproic acid in obese and lean patients with epilepsy","volume":"52","author":"Suemaru","year":"1998","journal-title":"Acta Med. Okayama"},{"key":"10.1016\/j.ejps.2017.10.009_bb0450","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00007691-199704000-00006","article-title":"Pharmacokinetics of valproic acid in patients with juvenile myoclonic epilepsy on monotherapy","volume":"19","author":"Sundqvist","year":"1997","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2017.10.009_bb0455","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","article-title":"The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients","volume":"112","author":"Tan","year":"2010","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.ejps.2017.10.009_bb0460","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0378-5173(01)00916-4","article-title":"Carbapenem antibiotics inhibit valproic acid transport in Caco-2 cell monolayers","volume":"233","author":"Torii","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.10.009_bb0465","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bcp.12234","article-title":"Combining the \u2018bottom up\u2019 and \u2018top down\u2019 approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data","volume":"79","author":"Tsamandouras","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0470","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40495-016-0060-3","article-title":"Top-down, bottom-up and middle-out strategies for drug cardiac safety assessment via modelling and simulations","volume":"2","author":"Tylutki","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"key":"10.1016\/j.ejps.2017.10.009_bb0475","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2006.02588.x","article-title":"Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation","volume":"61","author":"Uchaipichat","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0480","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1124\/dmd.113.051656","article-title":"The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs","volume":"41","author":"Uchaipichat","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.10.009_bb0485","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1021\/js980236p","article-title":"General solution for diffusion-controlled dissolution of spherical particles. 1. Theory","volume":"88","author":"Wang","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.10.009_bb0490","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jps.10039","article-title":"General solution for diffusion-controlled dissolution of spherical particles. 2. Evaluation of experimental data","volume":"91","author":"Wang","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.10.009_bb0495","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1210\/en.2013-2013","article-title":"Human UGT1A4 and UGT1A3 conjugate 25-hydroxyvitamin D3: metabolite structure, kinetics, inducibility, and interindividual variability","volume":"155","author":"Wang","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejps.2017.10.009_bb0500","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1124\/dmd.111.044057","article-title":"Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance","volume":"40","author":"Wattanachai","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.10.009_bb0505","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","article-title":"In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)","volume":"52","author":"Wen","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0510","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1212\/WNL.33.11.1474","article-title":"Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures","volume":"33","author":"Wilder","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.ejps.2017.10.009_bb0515","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00007691-198412000-00006","article-title":"Clinical implications of serum protein binding in epileptic children during sodium valproate maintenance therapy","volume":"6","author":"Yu","year":"1984","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2017.10.009_bb0520","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/j.1552-4604.1997.tb04301.x","article-title":"Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics","volume":"37","author":"Yukawa","year":"1997","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.009_bb0525","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"Zaccara","year":"2014","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.ejps.2017.10.009_bb0530","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-198815060-00002","article-title":"Clinical pharmacokinetics of valproic acid\u20141988","volume":"15","author":"Zaccara","year":"1988","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.10.009_bb0535","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/clpt.2012.68","article-title":"Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions","volume":"92","author":"Zhao","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.10.009_bb0540","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring","volume":"29","author":"Zhou","year":"2007","journal-title":"Ther. Drug Monit."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717305535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717305535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:59:30Z","timestamp":1750942770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717305535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":110,"alternative-id":["S0928098717305535"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.10.009","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}